Previous 10 | Next 10 |
Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United States The first FDA-approved teriparatide with Forteo® 1-3 as the reference drug SAN DIEGO, June 12, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American...
SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William Blair Growth Stock Conference on June 9, 2020. The discussion will be vir...
Image source: The Motley Fool. Pfenex (NYSEMKT: PFNX) Q1 2020 Earnings Call May 07, 2020 , 4:30 p.m. ET Operator Continue reading
Pfenex Inc. (PFNX) Q1 2020 Earnings Conference Call May 7, 2020 4:30 PM ET Company Participants Eef Schimmelpennink – President and Chief Executive Officer Conference Call Participants Greg Gilbert – SunTrust Brandon Folkes – Cantor Fitzgerald Jason But...
Pfenex (NYSEMKT: PFNX ): Q1 GAAP EPS of -$0.31 misses by $0.07 . Revenue of $0.68M (-91.3% Y/Y) misses by $3.81M . Press Release More news on: Pfenex Inc., Earnings news and commentary, Healthcare stocks news, ,
SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform, Pfenex Expression Technology®, to develop next generation and novel protein therapeutics...
SAN DIEGO, April 24, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market close on Thursday, May 7, 2020. Pfenex will host a conference call and webcast to discuss it...
Athersys (NASDAQ: ATHX ) initiated with Outperform rating and $14 (528% upside) price target at SMBC Nikko. More news on: Athersys, Inc., Livongo Health, Inc., Pfenex Inc., Healthcare stocks news, Stocks on the move, , Read more ...
Janssen Signs Collaboration with ImmunoPrecise Antibodies Johnson & Johnson ( JNJ ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. ( IPATF ). The new deal offers Janssen an exclusive access to an array of novel...
NEW YORK , April 17, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pfenex Inc. ("Pfenex" or "the Company") (NASDAQ: PFNX). Investors who purchased Pfenex securities&...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Pfenex Inc. (NYSE American: PFNX) at an offer price of $12.00 per share in cash, plus one non-transferable contractua...
NEW YORK, NY / ACCESSWIRE / September 15, 2020 / Juan Monteverde , founder, and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: Pfenex Inc. (NYSE American: PFNX ) relating to it...
NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately s...